Clinical trial · Observational
OSA in Never Smokers With Lung Cancer
Obstructive Sleep Apnea in Never Smokers With Newly Diagnosed Lung Cancer: Prevalence and Impact on Prognosis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Previous studies have yielded inconsistent findings regarding the association between obstructive sleep apnea and the prevalence and mortality of lung cancer. Smoking history, a common risk factor for lung cancer, chronic obstructive pulmonary disease, and obstructive sleep apnea, may act as a confounding variable, limiting interpretation of the results. The aim of this study is to evaluate the prevalence of obstructive sleep apnea in never smokers with lung cancer and to determine the effect of obstructive sleep apnea on the prognosis of lung cancer. Enrolled patients will undergo respiratory polygraphy before beginning treatment for lung cancer. This prospective cohort includes both cross sectional and longitudinal analyses.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Obstructive Sleep Apnea | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Prevalence of obstructive sleep apnea in never smokers with lung cancer
- timeFrame
- 1 week
- description
- A primary outcome measure in a cross-sectional analysis of a prospective cohort study
- measure
- Effects of obstructive sleep apnea on lung cancer mortality and overall mortality
- timeFrame
- Follow up for 5 years
- description
- A primary outcome measure in a longitudinal analysis of prospective cohort study
Secondary outcomes (6)
- measure
- Association between apnea-hyponea index (AHI) and the stage of lung cancer
- timeFrame
- 1 week
- description
- A secondary outcome measure in a cross-sectional analysis of a prospective cohort study.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: \- Never smokers who are admitted to the Seoul National University Hospital and newly diagnosed with lung cancer, with ECOG Performance Status 0 or 1 Exclusion Criteria: * Patients who have received treatment for lung cancer before the enrollment * Patients who have received treatment for OSA before the enrollment * Patients with an expected life expectancy of less than 3 months * Patients with neuromuscular disease, chronic opioid medication use, or severe insomnia not controlled by medication * Patients receiving supplemental oxygen therapy due to underlying diseases including heart failure, chronic obstructive pulmonary disease, interstitial pulmonary disease, hypoventilation syndrome, stroke, or whose baseline oxygen saturation is less than 90% * Patients with unstable medical conditions within the preceding 3 months (hospitalization due to acute exacerbation of underlying lung disease, diagnosis of unstable angina or myocardial infarction, history of percutaneous coronary intervention or coronary artery bypass surgery, or diagnosis of transient ischemic attack or stroke) * Patients with an inability or unwillingness to provide informed consent
References
Publications (1)
- DERIVEDPark J, Kim SY, Jo SM, Park YS, Cho J. Obstructive sleep apnea in never-smokers with newly diagnosed lung cancer: a prospective study in a predominantly female Korean population. Sci Rep. 2026 Mar 23;16(1):14579. doi: 10.1038/s41598-026-45232-7. PMID 41872397